By: Mario Aguilar
Blue Note’s failure to clear the FDA hurdle offers a rare window into the regulatory challenges faced by digital therapeutics companies.
Mario Aguilar is a health tech reporter for STAT, with a background in covering technology and healthcare. He has written for various publications, including the Boston Globe Technology. Mario's work focuses on the intersection of technology and healthcare, covering topics such as telemedicine, digital therapeutics, wearable devices, and innovative healthcare solutions.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Mario Aguilar's coverage primarily focuses on the healthcare and pharmaceutical industry, with a keen interest in digital health, telehealth, health technology, and the pharmaceutical sector. He often includes press releases and cites data in his articles.
To effectively reach out to Mario Aguilar, consider providing insights or analysis based on reliable data related to digital health advancements, telehealth services, innovative health technologies, or significant developments within the pharmaceutical industry. Additionally, pitches about private sector announcements or government initiatives in these areas may align well with his coverage interests.
While there is no specific geographic focus mentioned for Mario's coverage area, it is essential to ensure that any pitched content aligns with global relevance or has implications beyond a specific region if applicable.
This information evolves through artificial intelligence and human feedback. Improve this profile .